Marker Therapeutics, Inc. (MRKR) 10-Year Financial Performance & Capital Metrics

MRKR • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutMarker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.Show more

Revenue $7M +99.1%
EBITDA -$11M +5.7%
Net Income -$11M -30.3%
EPS (Diluted) -1.19 +38.3%
Gross Margin -104.33% +51.4%
EBITDA Margin -168.69% +52.6%
Operating Margin -168.69% +61.7%
Net Margin -162.82% +34.5%
ROE -65.81% -34.5%
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 92 (top 8%)
✓Strong 5Y sales CAGR of 98.6%
✓Trading at only 0.9x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y98.63%

3Y74.44%

TTM-12.99%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-47.45%

EPS CAGR

10Y-

5Y-

3Y-

TTM-12.84%

ROCE

10Y Avg-136.15%

5Y Avg-68.18%

3Y Avg-62.73%

Latest-68.19%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	183.06K	205.99K	213.19K	466.79K	1.24M	3.51M	3.31M	6.59M
Revenue Growth %	-	-	-	0.13%	0.03%	1.19%	1.66%	1.83%	-0.06%	0.99%
Cost of Goods Sold+	0	0	5.25M	124M	12.76M	18.88M	3.16M	11.97M	10.42M	13.47M
COGS % of Revenue	-	-	28.68%	601.95%	59.87%	40.45%	2.55%	3.41%	3.15%	2.04%
Gross Profit+	0	0	-5.07M	-123.79M	-12.55M	-18.41M	-1.92M	-8.45M	-7.11M	-6.88M
Gross Margin %	-	-	-27.68%	-600.95%	-58.87%	-39.45%	-1.55%	-2.41%	-2.15%	-1.04%
Gross Profit Growth %	-	-	-	-23.43%	0.9%	-0.47%	0.9%	-3.4%	0.16%	0.03%
Operating Expenses+	6.16M	8.26M	6.41M	148.38M	9.98M	10.47M	37.56M	11.34M	7.48M	4.24M
OpEx % of Revenue	-	-	35.03%	720.3%	46.8%	22.43%	30.25%	3.23%	2.26%	0.64%
Selling, General & Admin	4.45M	4.69M	6.41M	24.38M	9.98M	10.47M	9.76M	11.34M	7.48M	4.24M
SG&A % of Revenue	-	-	35.03%	118.35%	46.8%	22.43%	7.86%	3.23%	2.26%	0.64%
Research & Development	1.71M	3.8M	5.25M	124M	12.76M	18.88M	27.79M	11.97M	10.42M	13.47M
R&D % of Revenue	-	-	28.68%	601.95%	59.87%	40.45%	22.38%	3.41%	3.15%	2.04%
Other Operating Expenses	0	1.83K	-183K	116.05M	-12.76M	-18.88M	0	-11.97M	-10.42M	-13.47M
Operating Income+	-6.16M	-8.49M	-11.48M	-148.17M	-22.53M	-28.89M	-39.48M	-19.79M	-14.58M	-11.12M
Operating Margin %	-	-	-62.71%	-719.3%	-105.67%	-61.88%	-31.79%	-5.63%	-4.4%	-1.69%
Operating Income Growth %	-0.83%	-0.38%	-0.35%	-11.91%	0.85%	-0.28%	-0.37%	0.5%	0.26%	0.24%
EBITDA+	-34.06M	0	0	0	-22.42M	-27.81M	-36.32M	-17M	-11.79M	-11.12M
EBITDA Margin %	-	-	-	-	-105.18%	-59.58%	-29.25%	-4.84%	-3.56%	-1.69%
EBITDA Growth %	-0.12%	1%	-	-	-	-0.24%	-0.31%	0.53%	0.31%	0.06%
D&A (Non-Cash Add-back)	-27.9M	8.49M	11.48M	148.17M	105.12K	1.08M	3.16M	2.79M	2.79M	2
EBIT	-34.05M	-2.46M	-11.3M	-147.97M	-22.53M	-28.71M	-41.88M	-19.79M	-14.58M	-11.12M
Net Interest Income+	0	0	0	253.72K	1.08M	148.74K	5.7K	248.06K	539.16K	437.01K
Interest Income	0	0	0	253.72K	1.08M	148.74K	5.7K	248.06K	539.16K	437.01K
Interest Expense	10.93K	0	0	0	0	0	0	0	0	0
Other Income/Expense	-27.91M	6.04M	497.87K	213.72K	1.1M	179.74K	-2.4M	15.09K	539.16K	437.01K
Pretax Income+	-34.07M	-2.46M	-10.98M	-147.96M	-21.43M	-28.71M	-41.88M	-19.78M	-14.04M	-10.68M
Pretax Margin %	-	-	-59.99%	-718.26%	-100.51%	-61.5%	-33.73%	-5.63%	-4.24%	-1.62%
Income Tax+	0	0	0	-214K	0	0	0	0	3.67K	49.95K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1.51%	0.59%	1%
Net Income+	-34.07M	-2.46M	-10.98M	-147.96M	-21.43M	-28.71M	-41.88M	-29.93M	-8.24M	-10.73M
Net Margin %	-	-	-59.99%	-718.26%	-100.51%	-61.5%	-33.73%	-8.52%	-2.49%	-1.63%
Net Income Growth %	-0.1%	0.93%	-3.47%	-12.47%	0.86%	-0.34%	-0.46%	0.29%	0.72%	-0.3%
Net Income (Continuing)	-34.07M	-2.46M	-10.98M	-147.96M	-21.43M	-28.71M	-41.88M	-19.78M	-14.05M	-10.73M
Discontinued Operations	0	0	0	0	0	0	0	-10.15M	5.81M	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-93.02	-3.31	-11.62	-77.50	-4.70	-6.10	-5.47	-3.58	-1.93	-1.19
EPS Growth %	0.61%	0.96%	-2.51%	-5.67%	0.94%	-0.3%	0.1%	0.35%	0.46%	0.38%
EPS (Basic)	-93.02	-3.56	-11.62	-77.50	-4.70	-6.10	-5.47	-3.58	-1.93	-1.19
Diluted Shares Outstanding	366.23K	7.42M	945.35K	1.91M	4.56M	4.7M	7.65M	8.35M	8.81M	8.98M
Basic Shares Outstanding	366.23K	6.89M	945.35K	1.91M	4.56M	4.7M	7.65M	8.35M	8.81M	8.98M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	6.65M	7.92M	5.18M	62M	45.49M	24.41M	45.98M	16.62M	17.13M	22.02M
Cash & Short-Term Investments	6.58M	7.85M	5.13M	61.75M	43.9M	21.35M	42.35M	11.78M	15.11M	19.19M
Cash Only	6.58M	7.85M	5.13M	61.75M	43.9M	21.35M	42.35M	11.78M	15.11M	19.19M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	108.18K	56.19K	1M	237	2.4M	1.03M	2.35M
Days Sales Outstanding	-	-	-	191.68	96.2	782.38	0.07	249.53	113.3	129.96
Inventory	0	0	0	0	0	0	0	0	-988.13K	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	141.72K	1.53M	0	1.15M	585.84K	988.13K	0
Total Non-Current Assets+	0	0	0	148K	872.7K	21.2M	22.15M	17.8M	0	0
Property, Plant & Equipment	0	0	0	148K	872.7K	21.2M	22.15M	17.8M	0	0
Fixed Asset Turnover	-	-	-	1.39x	0.24x	0.02x	0.06x	0.20x	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0	0	143	0	0
Total Assets+	6.65M	7.92M	5.18M	62.14M	46.36M	45.61M	68.14M	34.42M	17.13M	22.02M
Asset Turnover	-	-	0.04x	0.00x	0.00x	0.01x	0.02x	0.10x	0.19x	0.30x
Asset Growth %	28.61%	0.19%	-0.35%	11%	-0.25%	-0.02%	0.49%	-0.49%	-0.5%	0.29%
Total Current Liabilities+	28.01M	1.74M	1.52M	2.8M	1.99M	6.4M	12.9M	7.78M	3.07M	3.46M
Accounts Payable	691.09K	680K	1.01M	1.62M	993K	2.94M	5.14M	1.1M	961K	1.07M
Days Payables Outstanding	-	-	70.55	4.77	28.39	56.74	593.67	33.58	33.67	28.89
Short-Term Debt	53K	5K	5K	0	204.13K	0	0	0	0	0
Deferred Revenue (Current)	0	544.76K	493K	0	0	0	1000K	1000K	0	0
Other Current Liabilities	27.18M	724.8K	166.31K	465.57K	472.68K	1.69M	2.05M	2.93M	1.84M	86.95K
Current Ratio	0.24x	4.56x	3.40x	22.11x	22.83x	3.81x	3.56x	2.14x	5.57x	6.36x
Quick Ratio	0.24x	4.56x	3.40x	22.11x	22.83x	3.81x	3.56x	2.14x	5.89x	6.36x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	1.02M	685.18K	1.02M	1.62M	280.25K	11.87M	11.25M	7.04M	0	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	280.25K	11.87M	11.25M	7.04M	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	28.01M	1.74M	1.52M	2.8M	2.27M	18.27M	24.15M	14.82M	3.07M	3.46M
Total Debt+	53K	5K	5K	0	484.38K	12.26M	11.87M	7.62M	0	0
Net Debt	-6.52M	-7.85M	-5.12M	-61.75M	-43.42M	-9.1M	-30.48M	-4.17M	-15.11M	-19.19M
Debt / Equity	-	0.00x	0.00x	-	0.01x	0.45x	0.27x	0.39x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-563.75x	-	-	-	-	-	-	-	-	-
Total Equity+	-21.36M	6.18M	3.66M	59.34M	44.09M	27.34M	43.99M	19.6M	14.05M	18.56M
Equity Growth %	-19.87%	1.29%	-0.41%	15.22%	-0.26%	-0.38%	0.61%	-0.55%	-0.28%	0.32%
Book Value per Share	-58.33	0.83	3.87	31.08	9.67	5.81	5.75	2.35	1.60	2.07
Total Shareholders' Equity	-21.36M	6.18M	3.66M	59.34M	44.09M	27.34M	43.99M	19.6M	14.05M	18.56M
Common Stock	70.55K	8.42K	10.62K	45.44K	45.73K	50.73K	8.31K	8.41K	8.89K	10.71K
Retained Earnings	-133.51M	-145.82M	-157.42M	-306.11M	-327.53M	-356.24M	-398.12M	-428.05M	-436.29M	-447.02M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.34M	-6.51M	-8.44M	-14.48M	-18.28M	-20.03M	-27.28M	-26.97M	-16.44M	-10.91M
Operating CF Margin %	-	-	-46.1%	-70.29%	-85.76%	-42.92%	-21.97%	-7.68%	-4.97%	-1.66%
Operating CF Growth %	-0.99%	-0.5%	-0.3%	-0.72%	-0.26%	-0.1%	-0.36%	0.01%	0.39%	0.34%
Net Income	-34.07M	-2.46M	-10.98M	-147.96M	-21.43M	-28.71M	-41.88M	-19.78M	-14.05M	-10.73M
Depreciation & Amortization	0	0	0	0	286.58K	1.08M	3.16M	0	0	0
Stock-Based Compensation	1.71M	1.56M	2.74M	16.35M	0	5.23M	5.96M	0	858.27K	245.86K
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	27.91M	-5.87M	-497.87K	116.08M	5.34M	-31K	0	-2.43M	-6.1M	0
Working Capital Changes	109.72K	256.24K	302.37K	1.04M	-2.48M	2.4M	5.47M	-4.76M	2.85M	-424.87K
Change in Receivables	0	0	0	0	51.99K	55.63K	1M	-2.4M	1.37M	-1.32M
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	96.02K	257.58K	283.37K	1.24M	-963.97K	0	0	-1.32M	611.26K	8.76K
Cash from Investing+	0	0	0	-147.67K	-374.98K	-9.25M	-3.13M	-4.95M	18.66M	0
Capital Expenditures	0	0	0	-147.67K	-374.98K	-9.25M	-3.13M	0	0	0
CapEx % of Revenue	-	-	-	0.72%	1.76%	19.82%	2.52%	0%	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	-4.95M	18.66M	0
Cash from Financing+	10.78M	7.78M	5.72M	71.25M	816.48K	6.74M	52.56M	202.13K	1.11M	14.99M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	8.31M	5.5M	619.62K	4.37M	0	550K	3.09K	0	90.48K	62.16K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.34M	-6.51M	-8.44M	-14.63M	-18.66M	-29.29M	-30.41M	-26.97M	-16.44M	-10.91M
FCF Margin %	-	-	-46.1%	-71.01%	-87.52%	-62.74%	-24.49%	-7.68%	-4.97%	-1.66%
FCF Growth %	-0.99%	-0.5%	-0.3%	-0.73%	-0.28%	-0.57%	-0.04%	0.11%	0.39%	0.34%
FCF per Share	-11.86	-0.88	-8.93	-7.66	-4.09	-6.23	-3.97	-3.23	-1.87	-1.21
FCF Conversion (FCF/Net Income)	0.13x	2.65x	0.77x	0.10x	0.85x	0.70x	0.65x	0.90x	2.00x	1.02x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-39.7%	-223.15%	-469.72%	-41.44%	-80.37%	-117.42%	-94.14%	-48.95%	-65.81%
Return on Invested Capital (ROIC)	-	-	-	-	-	-229.06%	-186.5%	-102.59%	-152.14%	-
Gross Margin	-	-	-2768.43%	-60094.95%	-5887.41%	-3944.86%	-154.7%	-240.64%	-214.6%	-104.33%
Net Margin	-	-	-5998.99%	-71826.36%	-10050.92%	-6149.73%	-3372.68%	-851.87%	-248.76%	-162.82%
Debt / Equity	-	0.00x	0.00x	-	0.01x	0.45x	0.27x	0.39x	-	-
Interest Coverage	-563.75x	-	-	-	-	-	-	-	-	-
FCF Conversion	0.13x	2.65x	0.77x	0.10x	0.85x	0.70x	0.65x	0.90x	2.00x	1.02x
Revenue Growth	-	-	-	12.53%	3.5%	118.95%	166.01%	182.96%	-5.76%	99.06%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Grant	205.99K	213.19K	466.79K	-	3.51M	-	6.59M
Grant Growth	-	3.50%	118.95%	-	-	-	-
Related Party Service	-	-	-	-	-	3.5M	-
Related Party Service Growth	-	-	-	-	-	-	-
Service	-	-	-	-	5.5M	816.64K	-
Service Growth	-	-	-	-	-	-85.15%	-
Grant income	-	-	-	1.24M	-	-	-
Grant income Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Marker Therapeutics, Inc. (MRKR) reported $4.7M in revenue for fiscal year 2024.

Marker Therapeutics, Inc. (MRKR) grew revenue by 99.1% over the past year. This is strong growth.

Marker Therapeutics, Inc. (MRKR) reported a net loss of $14.3M for fiscal year 2024.

Dividend & Returns

Marker Therapeutics, Inc. (MRKR) has a return on equity (ROE) of -65.8%. Negative ROE indicates the company is unprofitable.

Marker Therapeutics, Inc. (MRKR) had negative free cash flow of $14.8M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Marker Therapeutics, Inc. (MRKR) 10-Year Financial Performance & Capital Metrics

MRKR • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $7M +99.1%
EBITDA -$11M +5.7%
Net Income -$11M -30.3%
EPS (Diluted) -1.19 +38.3%
Gross Margin -104.33% +51.4%
EBITDA Margin -168.69% +52.6%
Operating Margin -168.69% +61.7%
Net Margin -162.82% +34.5%
ROE -65.81% -34.5%
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 92 (top 8%)
✓Strong 5Y sales CAGR of 98.6%
✓Trading at only 0.9x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y98.63%

3Y74.44%

TTM-12.99%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-47.45%

EPS CAGR

10Y-

5Y-

3Y-

TTM-12.84%

ROCE

10Y Avg-136.15%

5Y Avg-68.18%

3Y Avg-62.73%

Latest-68.19%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	183.06K	205.99K	213.19K	466.79K	1.24M	3.51M	3.31M	6.59M
Revenue Growth %	-	-	-	0.13%	0.03%	1.19%	1.66%	1.83%	-0.06%	0.99%
Cost of Goods Sold+	0	0	5.25M	124M	12.76M	18.88M	3.16M	11.97M	10.42M	13.47M
COGS % of Revenue	-	-	28.68%	601.95%	59.87%	40.45%	2.55%	3.41%	3.15%	2.04%
Gross Profit+	0	0	-5.07M	-123.79M	-12.55M	-18.41M	-1.92M	-8.45M	-7.11M	-6.88M
Gross Margin %	-	-	-27.68%	-600.95%	-58.87%	-39.45%	-1.55%	-2.41%	-2.15%	-1.04%
Gross Profit Growth %	-	-	-	-23.43%	0.9%	-0.47%	0.9%	-3.4%	0.16%	0.03%
Operating Expenses+	6.16M	8.26M	6.41M	148.38M	9.98M	10.47M	37.56M	11.34M	7.48M	4.24M
OpEx % of Revenue	-	-	35.03%	720.3%	46.8%	22.43%	30.25%	3.23%	2.26%	0.64%
Selling, General & Admin	4.45M	4.69M	6.41M	24.38M	9.98M	10.47M	9.76M	11.34M	7.48M	4.24M
SG&A % of Revenue	-	-	35.03%	118.35%	46.8%	22.43%	7.86%	3.23%	2.26%	0.64%
Research & Development	1.71M	3.8M	5.25M	124M	12.76M	18.88M	27.79M	11.97M	10.42M	13.47M
R&D % of Revenue	-	-	28.68%	601.95%	59.87%	40.45%	22.38%	3.41%	3.15%	2.04%
Other Operating Expenses	0	1.83K	-183K	116.05M	-12.76M	-18.88M	0	-11.97M	-10.42M	-13.47M
Operating Income+	-6.16M	-8.49M	-11.48M	-148.17M	-22.53M	-28.89M	-39.48M	-19.79M	-14.58M	-11.12M
Operating Margin %	-	-	-62.71%	-719.3%	-105.67%	-61.88%	-31.79%	-5.63%	-4.4%	-1.69%
Operating Income Growth %	-0.83%	-0.38%	-0.35%	-11.91%	0.85%	-0.28%	-0.37%	0.5%	0.26%	0.24%
EBITDA+	-34.06M	0	0	0	-22.42M	-27.81M	-36.32M	-17M	-11.79M	-11.12M
EBITDA Margin %	-	-	-	-	-105.18%	-59.58%	-29.25%	-4.84%	-3.56%	-1.69%
EBITDA Growth %	-0.12%	1%	-	-	-	-0.24%	-0.31%	0.53%	0.31%	0.06%
D&A (Non-Cash Add-back)	-27.9M	8.49M	11.48M	148.17M	105.12K	1.08M	3.16M	2.79M	2.79M	2
EBIT	-34.05M	-2.46M	-11.3M	-147.97M	-22.53M	-28.71M	-41.88M	-19.79M	-14.58M	-11.12M
Net Interest Income+	0	0	0	253.72K	1.08M	148.74K	5.7K	248.06K	539.16K	437.01K
Interest Income	0	0	0	253.72K	1.08M	148.74K	5.7K	248.06K	539.16K	437.01K
Interest Expense	10.93K	0	0	0	0	0	0	0	0	0
Other Income/Expense	-27.91M	6.04M	497.87K	213.72K	1.1M	179.74K	-2.4M	15.09K	539.16K	437.01K
Pretax Income+	-34.07M	-2.46M	-10.98M	-147.96M	-21.43M	-28.71M	-41.88M	-19.78M	-14.04M	-10.68M
Pretax Margin %	-	-	-59.99%	-718.26%	-100.51%	-61.5%	-33.73%	-5.63%	-4.24%	-1.62%
Income Tax+	0	0	0	-214K	0	0	0	0	3.67K	49.95K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1.51%	0.59%	1%
Net Income+	-34.07M	-2.46M	-10.98M	-147.96M	-21.43M	-28.71M	-41.88M	-29.93M	-8.24M	-10.73M
Net Margin %	-	-	-59.99%	-718.26%	-100.51%	-61.5%	-33.73%	-8.52%	-2.49%	-1.63%
Net Income Growth %	-0.1%	0.93%	-3.47%	-12.47%	0.86%	-0.34%	-0.46%	0.29%	0.72%	-0.3%
Net Income (Continuing)	-34.07M	-2.46M	-10.98M	-147.96M	-21.43M	-28.71M	-41.88M	-19.78M	-14.05M	-10.73M
Discontinued Operations	0	0	0	0	0	0	0	-10.15M	5.81M	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-93.02	-3.31	-11.62	-77.50	-4.70	-6.10	-5.47	-3.58	-1.93	-1.19
EPS Growth %	0.61%	0.96%	-2.51%	-5.67%	0.94%	-0.3%	0.1%	0.35%	0.46%	0.38%
EPS (Basic)	-93.02	-3.56	-11.62	-77.50	-4.70	-6.10	-5.47	-3.58	-1.93	-1.19
Diluted Shares Outstanding	366.23K	7.42M	945.35K	1.91M	4.56M	4.7M	7.65M	8.35M	8.81M	8.98M
Basic Shares Outstanding	366.23K	6.89M	945.35K	1.91M	4.56M	4.7M	7.65M	8.35M	8.81M	8.98M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	6.65M	7.92M	5.18M	62M	45.49M	24.41M	45.98M	16.62M	17.13M	22.02M
Cash & Short-Term Investments	6.58M	7.85M	5.13M	61.75M	43.9M	21.35M	42.35M	11.78M	15.11M	19.19M
Cash Only	6.58M	7.85M	5.13M	61.75M	43.9M	21.35M	42.35M	11.78M	15.11M	19.19M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	108.18K	56.19K	1M	237	2.4M	1.03M	2.35M
Days Sales Outstanding	-	-	-	191.68	96.2	782.38	0.07	249.53	113.3	129.96
Inventory	0	0	0	0	0	0	0	0	-988.13K	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	141.72K	1.53M	0	1.15M	585.84K	988.13K	0
Total Non-Current Assets+	0	0	0	148K	872.7K	21.2M	22.15M	17.8M	0	0
Property, Plant & Equipment	0	0	0	148K	872.7K	21.2M	22.15M	17.8M	0	0
Fixed Asset Turnover	-	-	-	1.39x	0.24x	0.02x	0.06x	0.20x	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0	0	143	0	0
Total Assets+	6.65M	7.92M	5.18M	62.14M	46.36M	45.61M	68.14M	34.42M	17.13M	22.02M
Asset Turnover	-	-	0.04x	0.00x	0.00x	0.01x	0.02x	0.10x	0.19x	0.30x
Asset Growth %	28.61%	0.19%	-0.35%	11%	-0.25%	-0.02%	0.49%	-0.49%	-0.5%	0.29%
Total Current Liabilities+	28.01M	1.74M	1.52M	2.8M	1.99M	6.4M	12.9M	7.78M	3.07M	3.46M
Accounts Payable	691.09K	680K	1.01M	1.62M	993K	2.94M	5.14M	1.1M	961K	1.07M
Days Payables Outstanding	-	-	70.55	4.77	28.39	56.74	593.67	33.58	33.67	28.89
Short-Term Debt	53K	5K	5K	0	204.13K	0	0	0	0	0
Deferred Revenue (Current)	0	544.76K	493K	0	0	0	1000K	1000K	0	0
Other Current Liabilities	27.18M	724.8K	166.31K	465.57K	472.68K	1.69M	2.05M	2.93M	1.84M	86.95K
Current Ratio	0.24x	4.56x	3.40x	22.11x	22.83x	3.81x	3.56x	2.14x	5.57x	6.36x
Quick Ratio	0.24x	4.56x	3.40x	22.11x	22.83x	3.81x	3.56x	2.14x	5.89x	6.36x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	1.02M	685.18K	1.02M	1.62M	280.25K	11.87M	11.25M	7.04M	0	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	280.25K	11.87M	11.25M	7.04M	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	28.01M	1.74M	1.52M	2.8M	2.27M	18.27M	24.15M	14.82M	3.07M	3.46M
Total Debt+	53K	5K	5K	0	484.38K	12.26M	11.87M	7.62M	0	0
Net Debt	-6.52M	-7.85M	-5.12M	-61.75M	-43.42M	-9.1M	-30.48M	-4.17M	-15.11M	-19.19M
Debt / Equity	-	0.00x	0.00x	-	0.01x	0.45x	0.27x	0.39x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-563.75x	-	-	-	-	-	-	-	-	-
Total Equity+	-21.36M	6.18M	3.66M	59.34M	44.09M	27.34M	43.99M	19.6M	14.05M	18.56M
Equity Growth %	-19.87%	1.29%	-0.41%	15.22%	-0.26%	-0.38%	0.61%	-0.55%	-0.28%	0.32%
Book Value per Share	-58.33	0.83	3.87	31.08	9.67	5.81	5.75	2.35	1.60	2.07
Total Shareholders' Equity	-21.36M	6.18M	3.66M	59.34M	44.09M	27.34M	43.99M	19.6M	14.05M	18.56M
Common Stock	70.55K	8.42K	10.62K	45.44K	45.73K	50.73K	8.31K	8.41K	8.89K	10.71K
Retained Earnings	-133.51M	-145.82M	-157.42M	-306.11M	-327.53M	-356.24M	-398.12M	-428.05M	-436.29M	-447.02M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.34M	-6.51M	-8.44M	-14.48M	-18.28M	-20.03M	-27.28M	-26.97M	-16.44M	-10.91M
Operating CF Margin %	-	-	-46.1%	-70.29%	-85.76%	-42.92%	-21.97%	-7.68%	-4.97%	-1.66%
Operating CF Growth %	-0.99%	-0.5%	-0.3%	-0.72%	-0.26%	-0.1%	-0.36%	0.01%	0.39%	0.34%
Net Income	-34.07M	-2.46M	-10.98M	-147.96M	-21.43M	-28.71M	-41.88M	-19.78M	-14.05M	-10.73M
Depreciation & Amortization	0	0	0	0	286.58K	1.08M	3.16M	0	0	0
Stock-Based Compensation	1.71M	1.56M	2.74M	16.35M	0	5.23M	5.96M	0	858.27K	245.86K
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	27.91M	-5.87M	-497.87K	116.08M	5.34M	-31K	0	-2.43M	-6.1M	0
Working Capital Changes	109.72K	256.24K	302.37K	1.04M	-2.48M	2.4M	5.47M	-4.76M	2.85M	-424.87K
Change in Receivables	0	0	0	0	51.99K	55.63K	1M	-2.4M	1.37M	-1.32M
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	96.02K	257.58K	283.37K	1.24M	-963.97K	0	0	-1.32M	611.26K	8.76K
Cash from Investing+	0	0	0	-147.67K	-374.98K	-9.25M	-3.13M	-4.95M	18.66M	0
Capital Expenditures	0	0	0	-147.67K	-374.98K	-9.25M	-3.13M	0	0	0
CapEx % of Revenue	-	-	-	0.72%	1.76%	19.82%	2.52%	0%	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	-4.95M	18.66M	0
Cash from Financing+	10.78M	7.78M	5.72M	71.25M	816.48K	6.74M	52.56M	202.13K	1.11M	14.99M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	8.31M	5.5M	619.62K	4.37M	0	550K	3.09K	0	90.48K	62.16K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.34M	-6.51M	-8.44M	-14.63M	-18.66M	-29.29M	-30.41M	-26.97M	-16.44M	-10.91M
FCF Margin %	-	-	-46.1%	-71.01%	-87.52%	-62.74%	-24.49%	-7.68%	-4.97%	-1.66%
FCF Growth %	-0.99%	-0.5%	-0.3%	-0.73%	-0.28%	-0.57%	-0.04%	0.11%	0.39%	0.34%
FCF per Share	-11.86	-0.88	-8.93	-7.66	-4.09	-6.23	-3.97	-3.23	-1.87	-1.21
FCF Conversion (FCF/Net Income)	0.13x	2.65x	0.77x	0.10x	0.85x	0.70x	0.65x	0.90x	2.00x	1.02x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-39.7%	-223.15%	-469.72%	-41.44%	-80.37%	-117.42%	-94.14%	-48.95%	-65.81%
Return on Invested Capital (ROIC)	-	-	-	-	-	-229.06%	-186.5%	-102.59%	-152.14%	-
Gross Margin	-	-	-2768.43%	-60094.95%	-5887.41%	-3944.86%	-154.7%	-240.64%	-214.6%	-104.33%
Net Margin	-	-	-5998.99%	-71826.36%	-10050.92%	-6149.73%	-3372.68%	-851.87%	-248.76%	-162.82%
Debt / Equity	-	0.00x	0.00x	-	0.01x	0.45x	0.27x	0.39x	-	-
Interest Coverage	-563.75x	-	-	-	-	-	-	-	-	-
FCF Conversion	0.13x	2.65x	0.77x	0.10x	0.85x	0.70x	0.65x	0.90x	2.00x	1.02x
Revenue Growth	-	-	-	12.53%	3.5%	118.95%	166.01%	182.96%	-5.76%	99.06%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Grant	205.99K	213.19K	466.79K	-	3.51M	-	6.59M
Grant Growth	-	3.50%	118.95%	-	-	-	-
Related Party Service	-	-	-	-	-	3.5M	-
Related Party Service Growth	-	-	-	-	-	-	-
Service	-	-	-	-	5.5M	816.64K	-
Service Growth	-	-	-	-	-	-85.15%	-
Grant income	-	-	-	1.24M	-	-	-
Grant income Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Marker Therapeutics, Inc. (MRKR) reported $4.7M in revenue for fiscal year 2024.

Marker Therapeutics, Inc. (MRKR) grew revenue by 99.1% over the past year. This is strong growth.

Marker Therapeutics, Inc. (MRKR) reported a net loss of $14.3M for fiscal year 2024.

Dividend & Returns

Marker Therapeutics, Inc. (MRKR) has a return on equity (ROE) of -65.8%. Negative ROE indicates the company is unprofitable.

Marker Therapeutics, Inc. (MRKR) had negative free cash flow of $14.8M in fiscal year 2024, likely due to heavy capital investments.